Related Experiment Video
Updated: Sep 25, 2026
Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Open-label, randomised controlled, multicentre study evaluating higher valency pneumococcal vaccines (PCV15/PCV20)
Riffat Aslam1, Oluwasefunmi Akeju2, Elizabeth Clutterbuck2
1Department of Paediatrics, Oxford Vaccine Group, Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), University of Oxford, Oxford, England, UK riffat.aslam@paediatrics.ox.ac.uk.
Background:
Most recent childhood invasive pneumococcal disease in the UK is caused by serotypes not included in the currently used pneumococcal conjugate vaccine (PCV13). There is potential for additional protection with newer PCVs that have wider serotype coverage but there are no data on these vaccines being given in the 1+1 schedule used in the UK. This study will determine whether the PCV13 serotype-specific antibody responses to PCV15 and PCV20 given at 3 and 12 months (1+1 schedule) are non-inferior to PCV13 serotype-specific antibody responses to PCV13 given in the same schedule. It will also determine whether PCV13 serotype-specific antibody responses to PCV20 given at 2, 4 and 12 months (2+1 schedule) are non-inferior to PCV13 serotype-specific antibody response to PCV13 given at 3 and 12 months (1+1 schedule).
Methods:
This will be an open-label, randomised controlled multicentre study in 600 infants. Healthy infants will be enrolled at 8 weeks and randomised 1:1:1:1 to receive 2 doses (1+1) of either PCV15, PCV20 or PCV13 at 3 and 12 months of age or 3 doses (2+1) of PCV20 at 2, 4 and 12 months. Blood and nasal samples will be collected at specified intervals to assess serum and nasal IgG levels and carriage. Postprimary and postbooster IgG levels in the PCV15 and PCV20 arms will be compared against PCV13.
Ethics And Dissemination:
Ethical approval for this study has been obtained from the South Central-Hampshire A Research Ethics Committee (REC ref 24/SC/0222). The results will be disseminated via publication in a peer-reviewed journal and presentations at international conferences.
Trial Registration Number:
ISRCTN17673117.
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:29Respiratory Syncytial Virus Disease
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:51Vaccinations
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Drug Dosing: Infants and Children